Helen Albert

A study led by the Third Military Medical University in Chongqing, China, has identified three distinct molecular subgroups of non-alcoholic fatty liver disease (NAFLD) that are linked to disease severity and progression.

A combination of chronic kidney disease and type 2 diabetes significantly increases a person's risk of having heart disease at a younger age.

AbbVie acquired Cerevel Therapeutics and the rights to emraclidine in a US$8.7 billion deal announced ​ in December last year.

Researchers led by the Icahn School of Medicine at Mount Sinai have developed an artificial intelligence (AI)-based program that can accurately pick

The antibody therapy pembrolizumab can help improve disease-free survival in patients with soft tissue sarcoma.

Lausanne-based AC Immune has a focus on developing treatments for neurodegenerative diseases and has several immunotherapies in development targeting both Alzheimer's and Parkinson's disease.

A serious adverse event in the New York biotech’s phase 1/2 trial of its Rett syndrome gene therapy puts a question mark over the program.

Two Phase II trials for the lipoprotein(a) lowering drugs, muvalapin and zerlasiran, met their primary endpoints with big target reductions.

Researchers at the École de Technologie Supérieure in Montreal and Dartmouth College in New Hampshire have created an in-ear device that can listen for early signs of Alzheimer's disease or similar conditions.

The promising trial results put icotrokinra on track to fulfill its potential as a best in class oral therapeutic for the chronic skin condition.